Interview: Current and future vaccine safety aspects
Posted: 4 March 2021 | Merck | No comments yet
Key requirements to ensure patient safety in the present-day development and production of viral vaccines, and the challenges going forward.
COVID-19 has drawn attention to the patient safety aspects of developing and manufacturing viral vaccines. This interview gives insights into the issues and obstacles faced by pharmaceutical companies, the current regulatory framework, and what Merck is doing to prepare itself and its customers for the inevitable next outbreak requiring the speedy development of a vaccine as well as streamlined and fast, but also safe, manufacture.
Related content from this organisation
- Formulation development outsourcing market to be worth over $60bn by 2030
- Pursuing new paths in targeted protein degradation drug development
- Efficient shutdown recovery: leveraging RMM to unlock value and ensure environmental quality
- Improved outcome for prostate cancer patients in Phase III PROpel trial
- Testing non-inferiority for accuracy of quantitative microbiological methods
Related topics
Analytical techniques, Biopharmaceuticals, Formulation, Manufacturing, QA/QC, Regulation & Legislation, Research & Development (R&D)
